Technical Analysis for CATB - Catabasis Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade C 7.45 4.78% 0.34
CATB closed up 4.78 percent on Wednesday, March 20, 2019, on 1.53 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical CATB trend table...

Date Alert Name Type % Chg
Mar 20 Pocket Pivot Bullish Swing Setup 0.00%
Mar 20 Calm After Storm Range Contraction 0.00%
Mar 20 Upper Bollinger Band Walk Strength 0.00%
Mar 20 Wide Bands Range Expansion 0.00%
Mar 20 Above Upper BB Strength 0.00%
Mar 20 Overbought Stochastic Strength 0.00%
Mar 20 Upper Bollinger Band Touch Strength 0.00%
Mar 19 200 DMA Support Bullish 4.78%
Mar 19 Upper Bollinger Band Walk Strength 4.78%
Mar 19 Inside Day Range Contraction 4.78%

Older signals for CATB ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Catabasis Pharmaceuticals, Inc. (Catabasis) is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapeutics based on its safely metabolized and rationally targeted (SMART) linker technology platform. Its SMART linker technology platform is based on the concept of treating diseases by simultaneously modulating various biological targets in one or more related disease pathways. Catabasis engineers bi-functional product candidates that are conjugates of two molecules, or bioactives, each with known pharmacological activity, joined by one of its SMART linkers. Catabasis is also engaged in developing other product candidates for the treatment of lipid disorders. The Company's product development pipeline includes three clinical-stage product candidates, namely, CAT-1004, CAT-2000 series, including CAT-2054 and CAT-2003, and CAT-4001, and various programs in preclinical development.
Biopharmaceutical Diseases Lipid Disorders Cat
Is CATB a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 20.7
52 Week Low 3.6
Average Volume 219,993
200-Day Moving Average 7.0212
50-Day Moving Average 5.4734
20-Day Moving Average 5.531
10-Day Moving Average 6.17
Average True Range 0.4457
ADX 31.93
+DI 46.3458
-DI 8.8922
Chandelier Exit (Long, 3 ATRs ) 6.3829
Chandelier Exit (Short, 3 ATRs ) 5.6871
Upper Bollinger Band 7.2842
Lower Bollinger Band 3.7778
Percent B (%b) 1.05
BandWidth 63.395408
MACD Line 0.5124
MACD Signal Line 0.233
MACD Histogram 0.2793
Fundamentals Value
Market Cap 167.48 Million
Num Shares 22.5 Million
EPS -1.71
Price-to-Earnings (P/E) Ratio -4.36
Price-to-Sales 0.00
Price-to-Book 2.17
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 8.28
Resistance 3 (R3) 8.27 8.00 8.14
Resistance 2 (R2) 8.00 7.79 8.00 8.09
Resistance 1 (R1) 7.72 7.66 7.86 7.73 8.05
Pivot Point 7.45 7.45 7.52 7.45 7.45
Support 1 (S1) 7.17 7.24 7.31 7.18 6.85
Support 2 (S2) 6.90 7.11 6.90 6.81
Support 3 (S3) 6.62 6.90 6.76
Support 4 (S4) 6.63